DLX 0110Alternative Names: DLX0110
Latest Information Update: 07 Aug 2007
At a glance
- Originator DELEX Therapeutics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Pain
Most Recent Events
- 04 May 2005 DELEX Therapeutics has been acquired by YM BioSciences
- 27 Aug 2003 Preclinical trials in Pain in Canada (unspecified route)